Retraction: Barlogie et al. Duration of Survival in Patients with Myeloma Treated with Thalidomide. N Engl J Med 2008;359:210-2.

doi:10.1056/NEJMc086378

Volume 359:1410		September 25, 2008		Number 13

Retraction: Barlogie et al. Duration of Survival in Patients with Myeloma Treated with Thalidomide. N Engl J Med 2008;359:210-2.

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

Full Text

PDF

PDA Full Text

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

Related Article

PubMed Citation

To the Editor: We wish to retract our letter to the editor,"Duration of Survival in Patients with Myeloma Treated withThalidomide," which was published in the Journal on July 10,2008.¹ The content of this letter, submitted in February 2008and accepted by the Journal in March 2008, largely duplicatesthe data that were published online by Blood on May 20, 2008.²

Bart Barlogie, M.D., Ph.D.
John D. Shaughnessy, Jr., Ph.D.
University of Arkansas for Medical Sciences
Little Rock, AR 72205
barlogiebart@uams.edu

John Crowley, Ph.D.
Cancer Research and Biostatistics
Seattle, WA 98101

Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-212. [Free Full Text]
Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008 May 20 (Epub ahead of print). DOI: 10.1182/blood-2008-03-145235.

Related Letters:

Duration of Survival in Patients with Myeloma Treated with Thalidomide
Barlogie B., Shaughnessy J. D. Jr., Crowley J.
Extract | Full Text | PDF
N Engl J Med 2008; 359:210-212, Jul 10, 2008. Correspondence